Bearing the above in mind, the Association of Innovative Pharmaceutical Companies INFARMA commissioned HTA Consulting firm to prepare the report "The indirect costs in health technology assessment in Poland". The aim of the report is to present the methodology of evaluation of indirect costs in the analysis of health technology assessment and conducting a pilot study for a specific disease entity.

INFARMA is of the opinion that there is a great need to increase access to innovative therapies in Poland. As a result, the effectiveness of treatment would increase, and thus spending in other areas would decrease – spending borne not only by the NHF, but also other institutions financed by taxpayers, for example ZUS.